Evaluation of prophylactic polyclonal anti-D antibodies: Differences in Fc-glycosylation in commercial products

Vox Sang. 2022 Apr;117(4):624-625. doi: 10.1111/vox.13213. Epub 2021 Oct 26.

Authors

Filippo Mori¹, Alfonso Salvatore², Ester Ascione², Raffaele Di Marzo³, Bernard Fox⁴

Affiliations

¹ Department of Research and Innovation, Kedrion S.p.A., Lucca, Italy.
² Department of Industrial Development, Kedrion S.p.A., Naples, Italy.
³ Therapeutic Area Lead, Global Medical Affairs Department, Kedrion S.p.A., Lucca, Italy.
⁴ Biotherapeutics Division, National Institute for Biological Standards and Control (NIBSC), Potters Bar, Herts, UK.

No abstract available

Publication types

Letter

MeSH terms

Glycosylation
Humans
Immunoglobulin Fc Fragments / metabolism
Immunoglobulin G*
Rho(D) Immune Globulin*

Substances

Immunoglobulin Fc Fragments
Immunoglobulin G
RHO(D) antibody
Rho(D) Immune Globulin

Grants and funding

This study was funded by Kedrion Biopharma Inc.